Every material Form 8-K BXP has filed with the SEC since July 30, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BXP, Inc. reported third-quarter 2026 results for the period ended September 30, 2026, with net income attributable to BXP of $114.5 million, or $0.71 per diluted share, compared with $68.6 million, or $0.43 per diluted share, in the prior quarter. Revenue rose to $911.4 million from $895.7 million, and diluted FFO per share increased to $1.89 from $1.78. The company also reiterated full-year 2026 guidance of $2.35 to $2.37 in diluted EPS and $7.06 to $7.08 in diluted FFO per share.
Q3 2026 net income attributable to BXP was $114.5 million, or $0.71 per diluted share, versus $68.6 million, or $0.43, in Q2 2026.
Total revenue was $911.4 million, up from $895.7 million in Q2 2026; FFO attributable to BXP was $302.2 million, up from $283.4 million.
Full-year 2026 guidance: projected diluted EPS of $2.35 to $2.37 and diluted FFO per share of $7.06 to $7.08.
Q3 2026 included a $6.0 million accelerated vesting charge in Q2 2026 and a $0.7 million deferred compensation gain in G&A; Q2 2026 included an $18.0 million impairment loss.
BXP reported second quarter 2026 results on July 28, 2026, with revenue of $895.7 million and diluted FFO of $1.78 per share, both up from the first quarter. Net income attributable to BXP fell to $68.6 million, or $0.43 per share, from $101.6 million, or $0.64 per share, in the first quarter, which included larger gains on sales. The company also gave full-year 2026 diluted FFO guidance of $6.99 to $7.05 per share and third-quarter guidance of $1.80 to $1.82.
Revenue rose to $895.7 million from $872.1 million in the first quarter of 2026.
Diluted FFO per share was $1.78, up from $1.59; FFO attributable to BXP was $283.4 million, up from $252.2 million.
Net income attributable to BXP was $68.6 million, or $0.43 per share, down from $0.64 per share; an $18.0 million impairment on the Sumner Square leasehold in Washington, DC was recorded.
Full-year 2026 guidance is $2.14 to $2.24 diluted EPS and $6.99 to $7.05 diluted FFO per share; third-quarter guidance is $0.50 to $0.52 EPS and $1.80 to $1.82 FFO per share.
On May 27, 2026, a BXP subsidiary agreed to sell three Washington, DC buildings on Sumner Square for a gross price of $63 million, as part of the asset sales plan from its September 2025 Investor Day. Because the property's carrying value exceeds expected net proceeds, BXP will record a non-cash impairment loss of approximately $18 million in the second quarter of 2026, which the company expects to cut earnings per diluted share by about $0.10 but not affect Funds from Operations. The sale is not assured to close on current terms.
Gross purchase price of $63 million for the Sumner Square leasehold and three buildings in Washington, DC
Non-cash impairment loss of approximately $18 million at BXP, Inc. and $17 million at BPLP, recorded in Q2 2026
Expected reduction of about $0.10 per diluted share/unit to net income for Q2 and full-year 2026; no impact on Funds from Operations
Buyer paid a non-refundable cash deposit of approximately $6 million, to be credited at closing
BXP, Inc. reported results for the quarter ended March 31, 2026, furnishing a press release and supplemental data on April 28, 2026. Net income attributable to BXP fell to $101.6 million, or $0.64 per diluted share, from $248.5 million, or $1.56 per share, in the prior quarter, and diluted FFO per share fell to $1.59 from $1.76. The filing also sets Q2 2026 and full-year 2026 guidance, but it does not state whether these ranges changed from earlier guidance.
Net income attributable to BXP, Inc.: $101.6 million, or $0.64 per diluted share, for the quarter ended March 31, 2026, versus $248.5 million, or $1.56 per share, for the quarter ended December 31, 2025.
Diluted FFO per share: $1.59, versus $1.76 in the prior quarter.
Total revenue: $872.1 million, versus $877.1 million in the prior quarter.
Guidance: Q2 2026 diluted EPS of $0.44 to $0.46 and FFO of $1.69 to $1.71 per share; full-year 2026 EPS of $2.15 to $2.29 and FFO of $6.90 to $7.04 per share.
BXP reported fourth-quarter and full-year 2025 results on January 27, 2026. Net income attributable to BXP was $248.5 million, or $1.56 per diluted share, compared with a loss of $121.7 million in the third quarter, and diluted FFO per share rose to $1.76 from $1.74. The company also issued 2026 guidance of $2.08 to $2.29 in diluted EPS and $6.88 to $7.04 in diluted FFO per share, though funds available for distribution fell to $134.5 million from $201.8 million.
Q4 2025 net income attributable to BXP was $248.5 million, or $1.56 per diluted share, versus a loss of $121.7 million, or $0.77 per share, in Q3 2025.
Q4 2025 revenue was $877.1 million, up from $871.5 million, and diluted FFO per share was $1.76, up from $1.74.
Full-year 2026 guidance: diluted EPS of $2.08 to $2.29 and diluted FFO per share of $6.88 to $7.04.
Funds available for distribution fell to $134.5 million from $201.8 million, and the FAD payout ratio rose to 92.09% from 61.37%.
BXP amended and restated the employment agreement of CEO and Chairman Owen D. Thomas, extending his term through December 31, 2029, from a previous expiration in December 2026. The company also granted equity awards under a 2025 Outperformance Plan to Mr. Thomas and other senior leaders, which vest only if BXP's dividend-adjusted stock price reaches set levels, and it expects about $11.6 million of related expense in 2026.
Term runs from December 22, 2025 through December 31, 2029; base salary stays at $950,000 and target bonus is $2,350,000
Outperformance Plan grants could total up to 711,864 LTIP Units; Mr. Thomas's grant is 211,864 units at maximum
Awards require a dividend-adjusted stock price of at least $90.00 for 20 consecutive trading days to earn any units; maximum requires $118.00
BXP expects about $32.1 million of OPP compensation expense over four years, including about $11.6 million, or $0.07 per share, in 2026
BXP reported third-quarter 2025 results showing a net loss attributable to BXP of $121.7 million, or $0.77 per diluted share, compared with net income of $89.0 million, or $0.56 per share, in the prior quarter. Revenue rose slightly to $871.5 million and diluted FFO per share increased to $1.74 from $1.71, but the loss reflects a non-cash impairment charge of approximately $145.1 million tied to unconsolidated joint ventures and $68.9 million of impairment losses on pending dispositions.
Net loss attributable to BXP of $121.7 million, or $0.77 per diluted share, for the quarter ended September 30, 2025, versus net income of $89.0 million, or $0.56 per share, for the quarter ended June 30, 2025
Total revenue of $871.5 million, up from $868.5 million in the prior quarter; diluted FFO per share of $1.74, up from $1.71
Non-cash impairment charge of approximately $145.1 million in loss from unconsolidated joint ventures, plus $68.9 million of impairment losses related to pending dispositions
Full-year 2025 guidance projects diluted EPS of $0.99 to $1.02 and diluted FFO per share of $6.89 to $6.92; quarterly dividend was $0.70 per share versus $0.98 in the prior quarter
On September 29, 2025, BXP's operating partnership, Boston Properties Limited Partnership, completed the sale of $1.0 billion of 2.00% exchangeable senior notes due October 1, 2030, including the full exercise of the initial purchasers' option for an additional $150 million. The notes can be exchanged into BXP common stock at an initial price of about $92.44 per share, which means dilution is possible if holders exchange and the partnership elects to settle in shares. The company said in its September 24 and 25 announcements that proceeds would largely be used to fund repayment of $1.0 billion of 3.650% senior notes maturing February 1, 2026.
Aggregate principal of $1.0 billion, including a $150 million option exercised in full, with a 2.00% annual interest rate payable April 1 and October 1 beginning April 1, 2026
Initial exchange price of approximately $92.44 per share, a premium of about 22.5% over the $75.46 last reported sale price on September 24, 2025
Pricing announcement stated estimated net proceeds of about $975.2 million if the option was exercised in full, with about $29.8 million used for capped call transactions
Notes are structurally subordinated to all existing and future liabilities of the partnership's subsidiaries and must be repaid or redeemed at maturity unless exchanged or repurchased
BXP, Inc. reported second-quarter 2025 results, with net income attributable to BXP of $89.0 million, or $0.56 per diluted share, up from $61.2 million, or $0.39 per share, in the first quarter of 2025. Diluted FFO per share rose to $1.71 from $1.64, and the company set 2025 full-year diluted EPS guidance of $1.74 to $1.82 and third-quarter EPS guidance of $0.41 to $0.43.
Revenue was $868.5 million for Q2 2025, compared with $865.2 million in Q1 2025.
Diluted FFO per share was $1.71 for Q2 2025, compared with $1.64 in Q1 2025.
Full-year 2025 guidance: diluted EPS of $1.74 to $1.82 and diluted FFO per share of $6.84 to $6.92.
Third-quarter 2025 guidance: diluted EPS of $0.41 to $0.43 and diluted FFO per share of $1.69 to $1.71.
BXP, Inc. reported first-quarter 2025 net income attributable to BXP of $61.2 million, or $0.39 per diluted share, compared with a loss of $230.0 million in the fourth quarter of 2024, which included about $341.3 million of impairment charges on unconsolidated joint ventures. Diluted FFO per share fell to $1.64 from $1.79, and the company also issued guidance for the second quarter and full year 2025, with full-year diluted EPS projected at $1.60 to $1.72 and FFO per share at $6.80 to $6.92.
Q1 2025 revenue was $865.2 million, up from $858.6 million in Q4 2024.
Net income attributable to BXP was $61.2 million ($0.39 per diluted share), versus a loss of $230.0 million ($1.45 per share) in Q4 2024.
Diluted FFO per share was $1.64, down from $1.79 in Q4 2024; in-service occupancy was 86.9%, versus 87.5%.
Guidance: Q2 2025 diluted EPS of $0.38 to $0.40 and FFO of $1.65 to $1.67 per share; full-year 2025 EPS of $1.60 to $1.72 and FFO of $6.80 to $6.92 per share.
BXP's operating partnership signed a First Amendment to its Tenth Amended and Restated Credit Agreement with Bank of America, N.A. as administrative agent. The amendment removes a 10 basis point SOFR conversion adjustment that applied to Closing Date Term Loans, on which the company had $700.0 million of principal outstanding. The filing states that other material terms of the credit agreement are unchanged, so the change is administrative in nature for shareholders.
Amendment dated April 22, 2025, to the Tenth Amended and Restated Credit Agreement dated March 28, 2025
Removes a 10 basis point SOFR conversion adjustment on Closing Date Term Loans
Company had $700.0 million in principal outstanding on those loans as of the amendment date
All other material terms of the credit agreement remain unchanged
BXP's operating partnership amended and restated its credit agreement on March 28, 2025, lifting the revolving commitment from $2.0 billion to $2.250 billion, extending its maturity to March 29, 2030, and adding a $700.0 million term loan that repaid an earlier $700.0 million term loan due May 2025. The changes lengthen the company's borrowing runway and extend the commercial paper backstop, though the filing also records $300.0 million drawn on the revolver after closing.
Total borrowing capacity under the 2025 Credit Facility is up to $2.950 billion, with an option to increase to $3.5 billion subject to syndication
Revolving Facility commitment rose from $2.0 billion to $2.250 billion and matures March 29, 2030
$300.0 million outstanding under the Revolving Facility after closing
Commercial paper program limit raised by $250.0 million to $750.0 million
BXP, Inc. reported a fourth-quarter 2024 net loss attributable to BXP of $230.0 million, or $1.45 per diluted share, compared with net income of $83.6 million, or $0.53 per share, in the prior quarter. The loss reflects impairment charges of about $341.3 million on investments in three unconsolidated joint ventures, while diluted FFO per share declined slightly to $1.79 from $1.81. Shareholders should note the impairment-driven loss and the 2025 guidance of $6.77 to $6.95 in diluted FFO per share.
Q4 2024 net loss attributable to BXP, Inc. of $230.0 million, or $1.45 per diluted share, versus $0.53 per share in Q3 2024
Impairment charges of about $341.3 million related to three unconsolidated joint ventures
Q4 2024 total revenue of $858.6 million versus $859.2 million in Q3 2024; diluted FFO per share of $1.79 versus $1.81
2025 guidance: full-year diluted FFO per share of $6.77 to $6.95 and first-quarter 2025 diluted FFO per share of $1.63 to $1.65
BXP reported third-quarter 2024 results on October 29, 2024, with net income attributable to BXP, Inc. of $83.6 million, or $0.53 per diluted share, up from $79.6 million, or $0.51, in the prior quarter. Revenue rose to $859.2 million from $850.5 million, and diluted FFO per share rose to $1.81 from $1.77. The filing also gives full-year 2024 guidance of $2.05 to $2.07 in diluted EPS and $7.09 to $7.11 in diluted FFO per share.
Net income attributable to BXP, Inc. was $83.6 million, or $0.53 per diluted share, versus $79.6 million, or $0.51, in the quarter ended June 30, 2024.
Total revenue was $859.2 million, compared with $850.5 million in the prior quarter.
Diluted FFO per share was $1.81, compared with $1.77; funds available for distribution fell to $219.1 million from $270.6 million.
Full-year 2024 guidance: projected diluted EPS of $2.05 to $2.07 and projected diluted FFO per share of $7.09 to $7.11.
BXP, Inc. reported second-quarter 2024 results on July 30, 2024, with revenue of $850.5 million, up from $839.4 million in the first quarter, and diluted FFO per share of $1.77, up from $1.73. Diluted EPS was $0.51, unchanged from the prior quarter, and the filing furnished full-year 2024 and third-quarter guidance for EPS and FFO per share. Same-property NOI excluding termination income fell 4.4% year over year in the quarter, compared with a 1.9% decline in the first quarter.
Total revenue of $850.5 million for the quarter ended June 30, 2024, versus $839.4 million in the prior quarter
Diluted FFO per share of $1.77 versus $1.73; diluted EPS of $0.51 in both quarters
Full-year 2024 guidance: projected diluted EPS of $2.08 to $2.14 and FFO per share of $7.09 to $7.15
Average in-service portfolio occupancy of 87.1% at June 30, 2024, down from 88.2% at March 31, 2024
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BXP filing is on SEC EDGAR ↗. 8-K briefs of other companies →